All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, February 27, 2021
Home » Blogs » BioWorld MedTech Perspectives » Old news, new news and non-news

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Old news, new news and non-news

Feb. 6, 2015
By Mark McCarty
No Comments

Ever heard a publisher say 'there's no news today'?
Ever heard a newspaper publisher say 'there's no news today'?

It’s fun trying to report the news, especially when there’s so much non-news masquerading as news. But I’m sure you’re tempted to say to yourself, “this old-news/new-news/non-news dilemma is news?”

Point taken. Anyway, let’s take a look at a couple of recent stories of note, newsy or not.

Old news; the combo products GMP guidance

FDA has issued a combination products draft guidance for good manufacturing practices compliance, but this is not the first such attempt and surely will not be the last.

FDA has taken several cracks at this topic, including a draft guidance in 2004, which came a scant two years after the agency formed the Office of Combination products. Following the 2004 effort, FDA announced in the Sept. 23, 2009, Federal Register that the GMP situation called for rulemaking when addressing single-entity and co-packaged combination products.

Barely four more years would pass when FDA announced yet again in the Jan. 22, 2013, Federal Register that it had finalized the rule developed in 2009, and the latest guidance points to the 2013 rule, noting that a set of GMP requirements had already been in place for human cells and other tissue-based therapeutic products.

This will prove to be one of the more iterative FDA guidances as the 21st Century unwinds if only because materials science is enabling a lot of advances that were previously just pipe dreams. There are a lot of advances in basic research of interest, including a story I wrote for the Dec. 17, 2014, issue of Medical Device Daily on an effort to create synthetic neural circuits based on mesenchymal stem cells (MSCs). Would the use of nanomaterials in addition to the MSCs make this a device or a biologic?

FDA will have to answer that and a whole lot of other questions as science pushes the envelope completely out of shape in the years ahead.

New news; Scientists aren’t always right

To be perfectly frank, this is hardly new news, but what’s a blog for if not the exercise of artistic license? There’s an article at the online portal for Perspectives on Psychological Science questioning whether science is as reliable as is often claimed.

Author John Ioannidis of the Stanford University Prevention Research Center takes up the question in the context of psychology, but anyone who attends FDA advisory meetings on a regular basis might see some of this in other branches of medical science, too. Among Ioannidis’ observations is that history “suggests that major catastrophes in scientific credibility are unfortunately possible,” and he stated further, “the argument that ‘it is obvious that progress is made’ is weak.”

I bring this up only because it is remarkable at times how routinely policymakers and the general public are inclined to accept the idea that a question is beyond dispute just because a scientist say "it’s this and not that."

Three cheers for civil religions, eh?

Non-news; guidance for trials for nail fungus

“Surely you jest, Mark,” you might say upon reading this. Nope, surely I don’t jest. FDA actually has a draft guidance out for clinical trials for treatments of fungal nail infections, said to be distinct from trials for products that clear nails that have been clouded by whatever, fungal nail infections included.

In addition to being stunningly small in scope, this draft guidance has an ick factor that is just off the charts. Oh, marone!

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Seniors with wooden puzzle

    Cassava’s simufilam improves AD patients’ cognition, behavior

    BioWorld
    When Cassava Sciences Inc.’s president and CEO, Remi Barbier, opened up the interim analysis of the company’s open-label study for Alzheimer’s disease candidate...
  • Vaxart COVID-19 vaccine tablets

    Vaxart shares shaken despite apparently positive early data for oral COVID-19 vaccine

    BioWorld
    Vaxart Inc. investors who stuck by company shares Feb. 3 had to swallow a bitter pill – watching shares of the oral vaccine developer (NASDAQ:VXRT) fall 57.8% to...
  • IPO money

    Lucira Health launches $153M IPO

    BioWorld MedTech
    Infectious diseases diagnostics company Lucira Health Inc. launched an IPO of 9 million shares of common stock at $17 per share, for expected gross proceeds of...
  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 26.
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing